Skip to main content

Table 4 FNA performance per cytology group

From: The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes

Performance on FN/SFN (n = 10)
Genetic alteration Histology malignant (n = 2) Histology benign (n = 8)
Positive 1 2
Negative 1 6
  1. Sensitivity, 50 % (1–99); Specificity, 75 % (35–97); PPV, 33 % (7–76); NPV, 86 % (59–96), prevalence of malignant lesions, 20 %. Estimated performance when malignancy is prevalent at 24 %: PPV, 39 % (9–80); NPV, 83 % (53–95)